大血管开放手术后静脉血栓栓塞药物预防时机与VTE风险的关联
研究基于密歇根外科质量协作组2012年7月至2015年6月数据,纳入2421例接受大型开放血管手术(oAAA修复、主股动脉旁路、下肢股下旁路)的患者,比较早期与延迟(>24小时)VTE药物预防对VTE发生率、输血率及30天死亡率与并发症的影响。
要点
- 大型开放血管手术后延迟VTE药物预防与VTE风险显著升高相关(OR 2.38)。
- 早期药物预防组出血风险显著低于延迟组(14.31% vs 18.90%)。
- 无禁忌时应考虑术后早期启动VTE药物预防。
核心结论
- 大型开放血管手术后延迟VTE药物预防与VTE风险显著升高独立相关。
- 早期药物预防组输血率更低且感染并发症更少,30天死亡率与总体并发症无差异。
研究设计与样本
- 回顾性队列研究,使用密歇根外科质量协作组(MSQC)2012年7月至2015年6月数据。
- 共纳入2421例大型开放血管手术患者,包括196例oAAA修复、259例主股动脉旁路、1966例下肢股下旁路。
- 延迟VTE药物预防定义为术后超过24小时启动。
- 采用多变量logistic回归分析风险校正后VTE与预防时机的关联。
主要发现
- 30天VTE总发生率为1.40%,其中下肢股下旁路1.12%、oAAA修复3.57%。
关键数值与推荐
- 延迟VTE药物预防定义为术后超过24小时启动。
- VTE总体30天发生率为1.40%,oAAA修复为3.57%,下肢股下旁路为1.12%。
临床怎么用
- 对于无禁忌证的大型开放血管手术患者,应考虑术后早期启动VTE药物预防。
- 早期药物预防未增加输血风险,且与更低的出血和感染并发症相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Venous thromboembolism (VTE) is reported to occur in up to 33% of patients undergoing major vascular surgery. Despite this high incidence, patients inconsistently receive timely VTE chemoprophylaxis. The true incidence of VTE among patients receiving delayed VTE chemoprophylaxis is unknown. We sought to identify the association of VTE chemoprophylaxis timing on VTE risk, postoperative transfusion rates, and 30-day mortality and morbidity in patients undergoing major open vascular surgery. METHODS: Patients undergoing major open vascular surgery (open abdominal aortic aneurysm [oAAA] repair, aortofemoral bypass, and lower extremity infrainguinal bypass [LEB]) were identified using the Michigan Surgical Quality Collaborative (MSQC) between July 2012 and June 2015. The VTE rate was compared between patients receiving early versus delayed VTE chemoprophylaxis. VTE chemoprophylaxis delay was defined as therapy initiation more than 24 hours after surgery. The risk-adjusted association of the chemoprophylaxis timing and VTE development was determined using multivariable logistic regression. Blood transfusion rates, 30-day mortality, and postoperative complications were compared across groups. RESULTS: A total of 2421 patients underwent major open vascular surgery, including 196 oAAA repair, 259 aortofemoral bypass, and 1966 LEB. The overall incidence of 30-day VTE was 1.40%, ranging from 1.12% for LEB to 3.57% for oAAA repair. Among patients receiving early VTE chemoprophylaxis, the rate of VTE was 0.78% versus 2.26% among those with a delay in VTE chemoprophylaxis (P = .002). When accounting for the preoperative risk of VTE, delayed chemoprophylaxis was associated with a significantly higher risk of VTE (odds ratio, 2.38; 95% confidence interval, 1.12-5.06; P = .024). The early VTE chemoprophylaxis group was associated with a significantly decreased risk of bleeding compared with those with a delay (14.31% vs 18.90%; P = .002). Overall 30-day mortality and postoperative complications were similar with the exception of an associated higher rate of infectious complications in the delayed VTE chemoprophylaxis group, including superficial surgical site infection (6.00% vs 4.06%; P = .028), pneumonia (3.25% vs 1.85%; P = .028), urinary tract infection (2.95% vs 1.57%; P = .020), and severe sepsis (3.05% vs 1.71%; P = .029). CONCLUSIONS: Although patients undergoing major open vascular surgery have a low risk of VTE at baseline, there is a significantly greater risk of developing VTE among patients who have a delay in the administration of VTE chemoprophylaxis. Postoperative transfusion rates were significantly lower among patients receiving early chemoprophylaxis. There were no differences in the 30-day mortality and postoperative complications, except for infectious complications. Given these findings, surgeons should consider early chemoprophylaxis in the postoperative setting after major open vascular surgery without contraindication.
引用
- Sutzko DC, Georgoff PE, Obi AT, et al. The association of venous thromboembolism chemoprophylaxis timing on venous thromboembolism after major vascular surgery. J Vasc Surg. 2017. PMID: 28870681. doi:10.1016/j.jvs.2017.06.087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。